For the quarter ending 2025-06-30, VRNA made $103,138K in revenue. $11,921K in net income. Net profit margin of 11.56%.
| Income Statement | 2025-06-30 | 2024-12-31 | 2024-09-30 | |
|---|---|---|---|---|
| Total revenue, net | 103,138 | 25,389* | 5,624 | |
| Research and development | 12,950 | 12,918* | 10,552 | |
| Cost of sales | 4,756 | 953* | 543 | |
| Selling, general and administrative | 72,127 | 44,144* | 35,196 | |
| Total operating expenses | 89,833 | 58,015* | 46,291 | |
| Operating income/(loss) | 13,305 | -32,626* | -40,667 | |
| Foreign exchange gain(loss) | - | - | 1,475 | |
| Research and development tax credit | 0 | -1,236* | 1,612 | |
| Interest expense | - | - | 9,882 | |
| Interest income | 4,302 | 1,012* | 4,750 | |
| Interest expense | 6,822 | 1,188* | - | |
| Loss on extinguishment of debt | 0 | -913* | - | |
| Foreign exchange gain/(loss) | 1,097 | -42* | - | |
| Total other (expense)/income, net | -1,423 | -2,367* | -2,045 | |
| Income/(loss) before income taxes | 11,882 | -34,993* | -42,712 | |
| Income tax benefit/(expense) | -39 | 9,539* | 250 | |
| Net income/(loss) | 11,921 | -44,532 | -42,962 | |
| Basic EPS | 0.02 | -0.068 | -0.07 | |
| Diluted EPS | 0.02 | -0.068 | -0.07 | |
| Basic Average Shares | 685,155,000 | 652,677,164 | 651,944,000 | |
| Diluted Average Shares | 727,223,000 | 652,677,164 | 651,944,000 | |
Verona Pharma plc (VRNA)
Verona Pharma plc (VRNA)